Avalo Therapeutics (AVTX) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$30.6 million.
- Avalo Therapeutics' Income from Continuing Operations fell 23293.83% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 115506.41%. This contributed to the annual value of -$35.1 million for FY2024, which is 1136.51% down from last year.
- Latest data reveals that Avalo Therapeutics reported Income from Continuing Operations of -$30.6 million as of Q3 2025, which was down 23293.83% from -$20.8 million recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Income from Continuing Operations ranged from a high of $98.5 million in Q2 2024 and a low of -$121.3 million during Q1 2024
- In the last 5 years, Avalo Therapeutics' Income from Continuing Operations had a median value of -$13.1 million in 2025 and averaged -$13.5 million.
- Over the last 5 years, Avalo Therapeutics' Income from Continuing Operations had its largest YoY gain of 130179.42% in 2024, and its largest YoY loss of 111838.27% in 2024.
- Quarter analysis of 5 years shows Avalo Therapeutics' Income from Continuing Operations stood at -$19.2 million in 2021, then surged by 48.77% to -$9.8 million in 2022, then increased by 16.75% to -$8.2 million in 2023, then tumbled by 332.65% to -$35.3 million in 2024, then grew by 13.34% to -$30.6 million in 2025.
- Its last three reported values are -$30.6 million in Q3 2025, -$20.8 million for Q2 2025, and -$13.1 million during Q1 2025.